LLYEli Lilly and CompanyRunning, no new patients
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Breast Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 8,000 (planned)
- Started
- Oct 4, 2022
- Main results expected
- Oct 2027
- Fully finished
- Mar 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Invasive Disease-Free Survival (IDFS)
Measured over: Randomization to recurrence or death from any cause (up to 10 years)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05514054 · record last updated 2026-04-02 · checked 2026-11-09 15:42 UTC